Drug Profile


Alternative Names: EV 576; PAS-coversin; rEV 576; Tissue targeted Coversin™ - Akari

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Complement C5 inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Guillain-Barre syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Preclinical Guillain-Barre syndrome; Haemolytic uraemic syndrome; Myasthenia gravis; Sjogren's syndrome
  • Discontinued Asthma; Autoimmune disorders; Inflammation

Most Recent Events

  • 05 Jan 2017 Akari Therapeutics plans a phase III trial for Paroxysmal nocturnal haemoglobinurea
  • 04 Jan 2017 Preclinical trials of tissue targeted form of Coversin™ in Myasthenia gravis in United Kingdom (unspecified route)
  • 29 Dec 2016 US FDA grants allowance for its IND of coversin to expand ongoing phase II trial in Paroxysmal nocturnal haemoglobinuria to the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top